Greater Cannabis Company (GCAN) Net Income towards Common Stockholders (2017 - 2026)
Greater Cannabis Company's (GCAN) quarterly Net Income towards Common Stockholders came in at -$33376.0 in Q1 2026, up 67.76% year-on-year from -$19895.6 in Q1 2025, and down 109.88% quarter-over-quarter from $337757.0 in Q4 2025.
Greater Cannabis Company (GCAN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$33376.0 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 67.76% year-over-year to -$33376.0 in Q1 2026; TTM through Mar 2026 was -$122571.0, a 48.49% increase from a year earlier, with the FY2025 full-year figure at -$331612.0, down 85.22% from the prior year.
- Net Income towards Common Stockholders eased to -$33376.0 in Q1 2026 per GCAN's latest filing, from $337757.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $337757.0 in Q4 2025 and bottomed at -$390853.0 in Q2 2025.
- The 5-year median for Net Income towards Common Stockholders is -$46165.0 (2024), against an average of -$56105.5.
- Biggest YoY gain for Net Income towards Common Stockholders was 879.18% in 2025; the steepest drop was 770.17% in 2025.
- Year by year, Net Income towards Common Stockholders stood at -$47401.0 in 2022, then gained by 1.14% to -$46861.0 in 2023, then rose by 7.5% to -$43348.0 in 2024, then soared by 879.18% to $337757.0 in 2025, then tumbled by 109.88% to -$33376.0 in 2026.
- Per Business Quant, the three latest GCAN Net Income towards Common Stockholders figures stand at -$33376.0 (Q1 2026), $337757.0 (Q4 2025), and -$36099.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Greater Cannabis Company | 255,226.94 | 255,226.94 | - | -33,376.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |